Sotera Health (NASDAQ:SHC) Price Target Raised to $20.00 at Citigroup

Sotera Health (NASDAQ:SHC) had its price target lifted by Citigroup from $18.00 to $20.00 in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Barclays lifted their target price on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Sotera Health Stock Performance

Shares of SHC stock opened at $16.11 on Wednesday. The company has a market capitalization of $4.56 billion, a price-to-earnings ratio of 115.07 and a beta of 2.08. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The company has a 50-day simple moving average of $15.96 and a 200 day simple moving average of $13.69.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. Sotera Health’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.18 EPS. On average, sell-side analysts predict that Sotera Health will post 0.64 earnings per share for the current year.

Insider Activity at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the sale, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 55.12% of the stock is owned by insiders.

Institutional Investors Weigh In On Sotera Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in SHC. Janus Henderson Group PLC raised its holdings in shares of Sotera Health by 43.6% during the 1st quarter. Janus Henderson Group PLC now owns 14,892,868 shares of the company’s stock worth $178,865,000 after buying an additional 4,525,056 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sotera Health by 27.0% in the first quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock worth $145,863,000 after acquiring an additional 2,579,248 shares during the last quarter. Darsana Capital Partners LP bought a new position in shares of Sotera Health in the second quarter worth about $29,074,000. Khrom Capital Management LLC acquired a new stake in shares of Sotera Health in the 1st quarter valued at approximately $14,626,000. Finally, AQR Capital Management LLC grew its holdings in shares of Sotera Health by 3,198.2% during the 2nd quarter. AQR Capital Management LLC now owns 511,580 shares of the company’s stock valued at $6,072,000 after purchasing an additional 496,069 shares during the last quarter. 91.03% of the stock is currently owned by institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.